Latest News

Cipla Finishes Q1FY19 On A Strong Note

One of the major Indian pharmaceutical company Cipla released their first quarterly financial report of the fiscal year of 2019 with 10% rise in net consolidated profit against the same period of previous fiscal year. Cipla reported the consolidated profit of Rs.451.25 crore which shows a 10.3% incline as compared to Rs. 408.82 crore of Q1FY18.

Cipla is India’s third largest drug-maker in terms of market capitalization, reported the total consolidated revenue of  Rs.3845.84 crore posting a 12% hike from Rs. 3432.32 crore of the corresponding quarter of previous fiscal period.

Cipla‘s profits from standalone operations grew by 50% to Rs. 390.55 crore in the quarter under review against Rs.259.1 crore of Q1FY18. Cipla’s business in India grew by 22% to reach Rs. 1544 crore which amount to 39% of company’s total sale. The company’s sale in North America also grew by 4% to Rs.670 crore.

Read EquityPandit’s Technical Analysis of Cipla

Get Daily Prediction & Stocks Tips On Your Mobile


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More